50 results about "Epilepsy therapy" patented technology

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention relates to the use of cannabidiol (CBD) in the treatment of epilepsy which results from mutation of the KCNT1 gene. The CBD used is in the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) is present in an amount of from 0.02 to 0.1% (w / w). In an alternative embodiment the CBD may be in a synthetic form. In use the CBD may also be used concomitantly with one or more other anti-epileptic drugs (AED). The CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

A system may be configured for treating a patient with epileptic seizures. The system may include a therapy delivery system configured to use a set of electrodes positioned adjacent to a spinal cord or dorsal column nuclei and a stimulation configuration to deliver neuromodulation energy to at least one target neural pathway in or near the spinal cord. The at least one target neural pathway includes the dorsal column nuclei or axons projecting to the dorsal column nuclei. The dorsal column nuclei and the axons are somatotopically organized and project to at least one of a cerebellum, a thalamus or a brainstem, which include somatotopically organized nuclei and project axons to different areas of a cortex. The at least one target neural pathway corresponds to at least one of the different areas of the cortex in which the epileptic seizures were located.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The present invention relates to a novel compound useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAA receptor complex.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The invention relates to an anti-epileptic polypeptide coupling medicine and a preparation method and application thereof, the polypeptide coupling medicine comprises an Fmoc protecting group, a permeation accelerating peptide and a cell penetrating peptide which are sequentially connected from the N end to the C end, and the permeation accelerating peptide is connected with an anti-epileptic medicine molecule. According to the invention, by fully utilizing the treatment requirements of epileptic seizure and the technical advantages of intranasal drug delivery, through the collaborative design of the protecting group, the functional polypeptide sequence and the anti-epileptic drug, the defects of poor brain targeting property, easy cyclization of a polypeptide carrier, low intranasal delivery efficiency and the like of the traditional anti-epileptic drug are overcome, non-invasive, efficient and low-toxicity epilepsy treatment is realized, and the application prospect is wide. And the preparation process is simplified, the clinical transformation requirement is met, and meanwhile, a new strategy is provided for non-invasive brain delivery of neuropeptide drugs.

This invention discloses the application of the inflammasome NLRP6 as a target in screening drugs for treating epilepsy, and the application of NLRP6 expression inhibitors in the preparation of drugs for treating epilepsy. This invention reveals for the first time the role of the inflammasome NLRP6 in epileptic neuroinflammation. This invention identifies NLRP6 as a key regulator of neuroinflammation in epilepsy and investigates its role in activating the caspase-1 / IL-1β / IL-18 signaling pathway. Knockdown of NLRP6 can improve the damaging effects of epilepsy on neurons, thereby improving seizures; overexpression of NLRP6 may exacerbate seizures, neuronal damage, and neuroinflammatory responses. This invention provides a new potential target for epilepsy treatment, offering new research ideas and directions.

The invention relates to an ultrasonic response bionic piezoelectric nano-drug for treating epilepsy as well as a preparation method and application of the ultrasonic response bionic piezoelectric nano-drug. The ultrasonic response bionic piezoelectric nano-drug comprises hafnium-based piezoelectric nano-particles UIO-66-NH2 etched by sulfuric acid, an anti-epileptic drug, a microglial cell membrane and transferrin receptor targeting peptide, wherein the anti-epileptic drug is loaded in hafnium-based piezoelectric nanoparticles etched by sulfuric acid to form a drug loading core; the microcolloid cell membrane coats the outer surface of the drug loading core; the transferrin receptor targeting peptide is connected to a microglial cell membrane. The ultrasonic response bionic piezoelectric nano-drug is high in brain entering efficiency, stable in drug release amount and clear in preparation method path, is suitable for targeted delivery of various anti-epileptic drugs and treatment and research of nervous system diseases such as epilepsy, can adopt an intravenous injection administration mode and non-invasive administration, can avoid injury caused by an operation, and has a good application prospect. The electrical stimulation is generated in vivo without implanting and taking out the electrode, so that secondary injury and infection are avoided.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking caffeine. Where the CBD is used in combination with caffeine, caution should be taken. For example, the dose of either the CBD and / or caffeine may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine, pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ8-dependent AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative diseases.

The invention belongs to the technical field of imidazopyridine derivatives based on piperidine connection, and discloses an (N-substituted-2-piperidyl)-imidazopyridine compound as well as a preparation method and application thereof. The anti-convulsion activity of the compound is evaluated by adopting subcutaneous pentyltetrazole (Sc-PTZ) and a mouse maximum electroconvulsion experiment (MES) model, and pharmacological experiment data shows that the compounds with the structures as shown in the formula I, the formula II and the formula III provided by the invention show clear and relatively strong anti-epileptic activity, and can be used for preparing anti-epileptic drugs. The conclusion proves that the (N-substituted-2-piperidyl)-imidazopyridine compounds with the structures of the formula I, the formula II and the formula III have the possibility of being developed into a novel epilepsy treatment medicine. # imgabs0 #

To provide a pharmaceutical composition containing cannabidiol (CBD) for reducing the total seizure frequency in treatment of treatment-resistant epilepsy (TRE).SOLUTION: A pharmaceutical composition containing cannabidiol (CBD) to be used for treating treatment-resistant childhood epilepsy, where the CBD is present at an amount of reducing the total seizure frequency by more than 50% for the frequency of seizure achieved by a combined antiepileptic drug (AED). The treatment-resistant childhood epilepsy includes Dravet syndrome, epilepsy with myoclonic absence, Lennox-Gastaut syndrome and the like, and the CBD is used in combination with one kind or a plurality of antiepileptic drugs (AED).SELECTED DRAWING: None

The invention discloses a pharmaceutical salt of lamotrigine, a pharmaceutical composition, a preparation method and application. Through a medicine-medicine combination strategy, lamotrigine and lipoic acid are combined in a salifying or mixture form, in epilepsy treatment, lamotrigine fragments can inhibit abnormal discharge and nerve over-excitation in the brain, and lipoic acid fragments can enhance the resistance of the brain to epileptic seizure, so that the epilepsy treatment effect is improved, and the epilepsy treatment effect is improved. The damage to the brain after the epileptic seizure is relieved, a multi-channel treatment effect with a synergistic effect is exerted, and the disease development is delayed. Meanwhile, the formed salt also has better physical and chemical stability, dissolution, pharmacokinetics and pharmacodynamic properties, is more beneficial to medicine formation on the whole, and provides an effective medicine for treating epilepsy.

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The present invention relates to a pharmaceutical composition for the prevention or treatment of epilepsy, and an epilepsy therapeutic agent screening method and a composition therefor, and specifically provides an epilepsy therapeutic agent screening method and an epilepsy therapeutic agent screening composition using induced pluripotent stem cells (iPSCs) derived from an epilepsy patient having a genotype comprising an SCN2A gene mutation, and accordingly, a pharmaceutical composition for the prevention or treatment of epilepsy having more excellent efficacy and selectivity than conventional epilepsy therapeutic agents may be screened and provided.

The present invention belongs to the field of electrophysiological signal detection technology, and specifically relates to an electrical stimulation system, a neural regulation device, and an epilepsy treatment device. The electrical stimulation system includes: a classifier; the input end of the classifier is the input feature of the signal after electrical stimulation, and the output end is the classification result of the effectiveness of electrical stimulation; wherein the input feature includes the proportion of stimulation channels with energy changes before and after electrical stimulation and\or the situation where the stimulation channels cover strongly connected nodes. By associating and binding the stimulation mode with the stimulation effect based on the data features of the EEG signal, the effectiveness of the stimulation mode can be effectively predicted in vitro or before the device is implanted, and the stimulation mode can be adjusted accordingly.

The invention discloses an application of inflammasome NLRP6 as a target spot in screening a medicine for treating epilepsy and an application of an NLRP6 expression inhibitor in preparing the medicine for treating epilepsy. The invention discloses the effect of the inflammasome NLRP6 in the aspect of epilepsy neuroinflammation for the first time. The invention researches and determines that the NLRP6 is used as a key regulatory factor of neuroinflammation in epilepsy, and researches the effect of the NLRP6 in activating a caspase-1 / IL-1beta / IL-18 signal channel. The NLRP6 is knocked down, so that the damage effect of epilepsy on neuronal cells can be improved, and the epileptic seizure is improved; overexpression of NLRP6 may aggravate epileptic seizure, neuron injury and neuroinflammatory response. The invention provides a new potential target for epilepsy treatment, and provides a new research thought and direction.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine formula for treating epilepsy, which is prepared from the following raw materials in parts by weight: 10-15 parts of lapis chloriti, 10-12 parts of bryozoatum, 8-10 parts of massa medicata fermentata fujianensis, 6-9 parts of acorus calamus, 9-12 parts of processed rhizoma pinelliae, 6-9 parts of processed rhizoma arisaematis, 3-6 parts of agilawood, 12-15 parts of radix rehmanniae, 12-15 parts of radix rehmanniae preparata, 3-6 parts of black semen pharbitidis and 3-6 parts of white semen pharbitidis. The preparation method comprises the following steps: step 1, pretreating the medicinal materials: calcining and quenching the lapis chloriti and the bryozoatum, and crushing into fine powder (passing through a 100-mesh sieve); cleaning the processed rhizoma pinelliae, the processed rhizoma arisaematis, the acorus calamus, the agilawood, the radix rehmanniae, the radix rehmanniae preparata and the massa medicata fermentata fujianensis, drying at 60-70 DEG C for 2 hours, and crushing into coarse powder; step 2, extracting and concentrating; step 3, mixing and forming; the traditional Chinese medicine formula for treating epilepsy provided by the invention has the beneficial effects that both symptoms and root causes are treated, the curative effect is remarkable, the preparation process is standardized, and the epileptic seizure symptom and physique basis are improved through accurate compatibility of products for reducing phlegm and inducing resuscitation, extinguishing wind and relieving convulsion, and nourishing yin and blood.

The invention discloses application of S-adenosylmethionine for treating epilepsy and a verification method, and relates to the technical field of epilepsy treatment. According to the invention, the epileptic seizure susceptibility and severity are reduced by intraperitoneal injection of S-adenosylmethionine, and pentamethylenetetrazine molding is carried out 14 days after intervention of S-adenosylmethionine, so that the incubation period of epileptic seizure can be effectively prolonged, and the severity of epileptic seizure is reduced; in addition, sea human acid modeling is carried out 14 days after S-adenosylmethionine intervention, S-adenosylmethionine intervention lasts for 30 days, the incubation period of spontaneous and repeated attack of epilepsy can be effectively prolonged, and the number of times of epilepsy attack is reduced; the method proves that S-adenosylmethionine has the effect of reducing epilepsy susceptibility and severity from the animal level, and a new way is provided for epilepsy treatment.

The invention discloses a method and system for predicting the first-time single-drug treatment effect of children epilepsy, and belongs to the technical field of multi-modal data process.The method comprises the steps that multi-modal data of a patient is obtained and preprocessed, key features are extracted from the preprocessed data, and the first-time single-drug treatment effect of children epilepsy is predicted; and inputting the key features as a model into a deep neural network for training to obtain an anti-epileptic seizure drug curative effect prediction model of a patient, and carrying out multi-modal data fusion on clinical data, electroencephalogram features and iconography features, so that factors influencing the curative effect of the anti-epileptic seizure drug can be comprehensively evaluated and analyzed from multiple perspectives. The prediction model can be applied to personalized recommendation of anti-epileptic seizure drugs, a treatment scheme is optimized, an epilepsy treatment delay period is shortened, patient prognosis is improved, and epilepsy treatment accuracy is improved.

The application discloses a 4-butyl-2,7-bis(2-fluorophenyl)-triazolopyrimidine-5(4H)-ketone compound and a preparation method and application thereof. The anti-convulsion activity of the compound is evaluated by adopting a subcutaneous pentylenetetrazol (Sc-PTZ) and a mouse maximum electroshock (MES) model, and the neurotoxicity of the compound is evaluated by adopting a rotating rod method; experimental data show that the target compound with the structure of formula I provided by the application has clear and strong anti-convulsion activity and extremely low neurotoxicity, and the conclusion proves that the compound with the structure of formula I has the possibility of being developed into a new type of epilepsy treatment drug with low neurotoxicity.

This invention discloses the application of the scorpion venom polypeptide BmK AS in the treatment of chronic epilepsy. BmK AS exerts potent anti-epileptic and neuroprotective effects through a confluence mechanism. In a lycine-induced mouse model, BmK AS significantly shortened seizure duration, reduced seizure frequency, prolonged seizure latency, and improved cognitive and mental outcomes. Electrophysiologically, BmK AS nonlinearly inhibited multiple VGSC subtypes, with a particularly significant effect on Nav1.6, reducing peak sodium current by 43% at a concentration of 5 nM. Furthermore, BmK AS alleviated hippocampal neuroinflammation by inhibiting the NLRP1 inflammasome pathway and related pyroptosis. This invention establishes BmK AS as a promising multi-mechanism therapeutic candidate, highlighting the value of a dual therapeutic strategy of Nav1.6 blockade and neuroinflammation suppression for epilepsy treatment.

Compositions and methods for administering ketone bodies to a subject include a beta-hydroxybutyrate ester of an alcohol, such as a sugar or sugar alcohol. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The application discloses a kind of for epilepsy treatment inhalation device, it is related to medical equipment technical field.The device includes medicament inhalation mechanism and with its communication gas source docking mechanism.Gas source docking mechanism is through the elastic combination design of upper shell, lower shell and is clamped nasal oxygen tube, and utilize the mechanical linkage of pulling member and double elastic piece, automatically switch oxygen drive and air drive mode: when connecting nasal oxygen tube, nasal cannula is covered by closed cover, oxygen is used as medicament driving gas source and maintaining patient oxygen inhalation;When not connecting, filtered air drives medicament.Core technology includes the curved surface sealing design of pulling member concave and the convex surface of docking cylinder dynamic air-tightness, and the one-hand operation logic of upper and lower pull ring.The application realizes the synergy of inhalation therapy and oxygen therapy, avoids therapeutic anoxia, has the advantages of quick response, convenient operation and compatibility existing nasal oxygen tube, especially suitable for emergency scene of critical case such as status epilepticus.

The invention discloses a sniffing device for epilepsy treatment, and relates to the technical field of medical equipment. The device comprises a medicament sniffing mechanism and a gas source docking mechanism communicated with the medicament sniffing mechanism. The air source butt joint mechanism clamps a nasal oxygen cannula through the elastic splicing design of an upper shell and a lower shell, and automatically switches an oxygen driving mode and an air driving mode through mechanical linkage of a pulling piece and a double-elastic piece: when the nasal oxygen cannula is connected, the nasal cannula is sealed and covered, and oxygen serves as a medicament to push an air source and maintain oxygen inhalation of a patient; when not connected, the filtered air drives the medicament. The core technology comprises the curved surface sealing design of the concave surface of the pulling piece and the convex surface of the butt joint cylinder to realize dynamic air tightness and the single-hand operation logic of the upper and lower pull rings. According to the invention, the cooperation of sniffing treatment and oxygen therapy is realized, therapeutic hypoxia is avoided, and the system has the advantages of quick response, convenience in operation and compatibility with the existing nasal oxygen cannula, and is particularly suitable for emergency scenes of critical cases such as epileptic status and the like.